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Protocol
AbstrACt
Introduction Sarcopenia (or loss of muscle mass and 
function) is a relatively new area within the field of 
musculoskeletal research and medicine. Investigating 
whether there is a social gradient, including occupation 
type and income level, of sarcopenia, as observed for 
other diseases, will contribute significantly to the limited 
evidence base for this disease. This new information may 
inform the prevention and management of sarcopenia and 
widen the evidence base to support existing and future 
health campaigns.
Methods and analysis We will conduct a systematic 
search of the databases PubMed, Ovid, CINAHL, 
Scopus and EMBASE to identify articles that investigate 
associations between social determinants of health 
and sarcopenia in adults aged 50 years and older. 
Eligibility of the selected studies will be determined 
by two independent reviewers. The methodological 
quality of eligible studies will be assessed according to 
predetermined criteria. Established statistical methods 
to identify and control for heterogeneity will be used, and 
where appropriate, we will conduct a meta-analysis. In the 
event that heterogeneity prevents numerical synthesis, a 
best evidence analysis will be employed. This systematic 
review protocol adheres to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses Protocols 
reporting guidelines and will be registered with the 
International Prospective Register of Systematic Reviews 
(PROSPERO).
Ethics and dissemination This systematic review will 
use published data, thus ethical permissions will not be 
required. In addition to peer-reviewed publication, our 
results will be presented at (inter)national conferences 
relevant to the field of sarcopenia, ageing and/
or musculoskeletal health and disseminated both 
electronically and in print.
PrOsPErO registration number CRD42017072253.
IntrOduCtIOn
WHO defines the social determinants of 
health as the conditions in which a person 
is born, lives, grows, works and ages1: social 
determinants encompass the distribution of 
economic and social conditions that influ-
ence individual and group differences in 
health status, and they include factors such as 
area-level or individual-level socioeconomic 
status, occupation type and level of income.1 2 
As such, social determinants have a profound 
influence in compromising health-related 
behaviours and health outcomes3: the muscu-
loskeletal system appears to be no exception 
to this,4–6 with the association having already 
been identified in conditions such as osteo-
porosis.7 There is now a strong evidence base 
for the role played by social disadvantage on 
an increased susceptibility to many chronic 
illnesses, lower uptake or engagement in 
preventative care and earlier mortality.2 8 
Sarcopenia is defined as a progressive and 
generalised decline in skeletal muscle mass 
and deficits of overall strength and func-
tionality.9–24 Two measures of sarcopenia are 
currently recommended; a combination of a 
low level of muscle mass and muscle function 
(a working definition proposed by the Euro-
pean Working Group on Sarcopenia in Older 
People)9 10 12; or, as an operational definition, 
muscle mass corrected for height that is two 
or more SD below that of a young healthy 
adult is sarcopenia.13 25 26 Sarcopenia is a 
relatively new term; although initially coined 
by Irwin Rosenberg in 1989,9 it was only 
added to the International Classification of 
strengths and limitations of this study
 ► This systematic review will focus on the newly 
defined disease of sarcopenia; a recent addition to 
the International Classification of Diseases, Tenth 
Revision, Clinical Modification. 
 ► The selection of eligible studies and methodological 
assessment will be independently confirmed by two 
authors. 
 ► Potential confounders and/or mediators of any 
observed relationship between social determinants 
and sarcopenia will be highlighted.
 ► Potential limitations of this review may be a paucity 
of data due to the ‘newness’ of sarcopenia and, 
plausibly, much heterogeneity in available studies.
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Diseases, Tenth Revision, Clinical Modification in 2016.27 
Given the current absence of a universal definition of 
sarcopenia,12 28 the nascent literature in this field pres-
ents varied estimates of prevalence.17 Nonetheless, there 
is agreement that the main consequences of sarcopenia 
include frailty, falls, hospitalisation, disability and earlier 
mortality,9 10 thereby increasing the burden on individ-
uals, communities and healthcare systems.9 20
In the context of the ‘newness’ of sarcopenia and the 
well-documented role of social determinants in other 
chronic diseases, we present the protocol for a systematic 
review, which aims to identify, collate and synthesise the 
evidence for a social gradient of sarcopenia.
MEthOds
This systematic review protocol has been registered 
with the International Prospective Register of System-
atic Reviews (registration ID: CRD42017072253), and 
it adheres to the preferred reporting process outlined 
within the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses Protocols (PRISMA-P) 2015 
guidelines.29
Criteria for considering studies in this review
Articles that investigate, in adult populations aged 50 years 
or older, the association between social determinants as 
risk factors and the outcome of sarcopenia (regardless 
of definition), and are epidemiological cohort, cross-sec-
tional and/or case–control studies by design, available in 
full text, and published in any language will be eligible 
for inclusion in this review.
Grey literature, conference presentations, opinions or 
commentaries and randomised controlled trials (RCTs) 
will be excluded. However, where possible, baseline data 
from RCTs that apply to social determinants of health and 
sarcopenia prior to the RCT intervention will be included, 
as it may be possible that these data may be able to offer 
relevant cross-sectional information.
search strategy and data extraction
An electronic search strategy will be performed to inves-
tigate medical, health and the social science databases 
(PubMed, Ovid, CINAHL and EMBASE) to identify studies 
that match our eligibility criteria, with no limits set for the 
year of publication. The following Medical Subject Head-
ings will be applied ‘[All Fields]: (sarcopenia OR aging OR 
muscular atrophy)’; and the following search strategy will 
be implemented ‘((sarcopenia) OR (aging) OR (muscular 
atrophy) OR (lean mass) OR (musculoskeletal aging)) 
AND ((social determinants) OR (ses) OR (income) 
OR (occupation) OR (socioeconomic))’. Keywords 
of lean mass and musculoskeletal ageing will also be 
included. For the complete search strategy, please refer to 
online  supplementary file 1 (PubMed search).
Relevant truncation will be applied to each database. 
One reviewer will perform the search strategy and iden-
tify eligible inclusion literature, and two further reviewers 
will endorse those articles identified as eligible for inclu-
sion. Professional interpreter assistance will be sought to 
confirm eligibility for articles written in a language other 
than English. The eligibility of studies will be checked in 
a three-step process: (1) assessing titles and abstracts, (2) 
assessing full-text papers and (3) hand-searching refer-
ence lists. The reference lists of the studies that have been 
deemed eligible will be independently hand-searched by 
two reviewers. One reviewer will extract data from studies 
deemed eligible for inclusion, and a further reviewer 
will cross-check all extracted data. Should disagreement 
arise regarding those data, a third will provide the final 
judgement.
Assessment of methodological quality of included articles
A modified scoring system from Lievense et al30 31 will 
be employed to analyse data extracted from included 
studies (table 1). Each of the eligible studies will be 
scored based on the previously mentioned methodolog-
ical assessment criteria, and the score given will be either 
positive or negative for each of the criterion within the 
study. Currently, no validated criteria exist for assessing 
Table 1 Criteria list for the assessment of methodological 
quality, modified from Lievense et al30 31
Item Criterion C/CC/CS
Study population
1 Uniform point (selection before disease 
was present)
C/CC/CS
2 Cases and controls drawn from the same 
population
CC
3 Participation rate >80% for cases/cohort C/CC/CS
4 Participation rate >80% for controls CC
Assessment of risk factor
5 Exposure assessment blinded C/CC/CS
6 Exposure measure identical for cases and 
controls
CC
7 Exposure assessed prior to the outcome C/CC/CS
Assessment of outcome
8 Outcome assessed identically in studied 
populations
C/CC/CS
9 Outcome assessed reproducibly C/CC/CS
10 Outcome assessed according to validated 
measures
C/CC/CS
Study design
11 Prospective design used C/CC
12 Follow-up time >12 months C
13 Withdrawals <20% C
Analysis and data presentation
14 Appropriate analysis techniques used C/CC/CS
15 Adjusted for at least age and sex C/CC/CS
C, applicable to cohort studies; CC, applicable to case–control 
studies; CS, applicable to cross-sectional studies.
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the methodological quality of observational studies; the 
Lievense et al30 31 tool provides a reproducible process and 
enables both validity and informativeness to be assessed 
in cohort, case–control and cross-sectional study designs, 
as we have previously demonstrated in the musculoskel-
etal research field.32–34 Those studies deemed eligible 
will be independently scored by two reviewers using the 
Lievense et al30 31 scoring system: should any differences in 
scores be found to be irreconcilable, a third reviewer will 
be introduced and provide the final judgement. The final 
score will be calculated (as a percentage) and ranked 
and deemed as having higher methodological quality if 
scored above the median of the total scores.
Presenting and reporting results
This systematic review protocol adheres to the PRISMA-P 
reporting guidelines.35 An adapted Quality of Reporting 
of Meta-analyses standards (QUORUM) diagram36 will be 
used to present study selection, numbers and reasons for 
inclusion and exclusion of articles in line with the prede-
termined eligibility criteria. All relevant studies will have 
key information regarding sarcopenia and social deter-
minants identified, manually extracted and presented, 
which will be from the articles eligible for inclusion. The 
key information to be extracted from eligible papers 
may include, but will not be limited to, the definition 
and measures of sarcopenia, lean mass and hand grip 
strength, socioeconomic status, income and education 
attainment. Results from the methodological scoring will 
be presented as a percentage.
Where methodological heterogeneity is low, a 
meta-analysis will be performed and a numerical synthesis 
presented. The determination of whether statistical 
heterogeneity is low enough to conduct a meta-analysis 
will be assessed using the Cochrane Q statistic and the I2 
statistic: this method will also inform whether we adopt 
a fixed-effects or random-effects model. We will apply a 
threshold of an I2 >50% to classify moderate heteroge-
neity and, if there is overall consistency in the direction 
of effect, the potential use of a random-effects model. 
Sources of heterogeneity will be investigated by removing 
studies at high risk of bias and comparing summary esti-
mates from different study-level methodological charac-
teristics (such as sarcopenia definitions, study design and 
age of population), using metaregression where appro-
priate. Funnel plots will be used to investigate publication 
bias, whereby the distribution of ORs will be presented 
according to sample size.
Where missing data are identified and to enable meth-
odological scoring using the Lievense et al30 31 multi-
item instrument, we will (1) employ inverse probability 
weighting and (2) report the number of missing items 
on which the inferences were based.37 We will present all 
available data in the eligible studies, noting where missing 
data preclude our ability to report.
A ‘best evidence syntheses’ will be undertaken where 
a meta-analysis is not possible, due to heterogeneity: this 
latter method will enable an evaluation of the combined 
level of evidence; ranging from no evidence to strong 
evidence (table 2), as previously published in the muscu-
loskeletal field.33 34
dissemination
Findings from this review will be published in a peer-re-
viewed scientific journal and presented at (inter)national 
conferences relevant to the field of sarcopenia and/or 
musculoskeletal health.
Ethics
Given that this systematic review will use only published 
data, ethical permissions will not be required. However, 
ethical and governance standards with regard to data 
management and the presentation and discussion of our 
findings will be strictly abided by within our research 
processes.
COnClusIOn
To the best of our knowledge, this will be the first review to 
explore whether there is a social gradient of sarcopenia. 
Investigating sarcopenia in relation to the social determi-
nants of health is a novel area of enquiry, and these find-
ings will contribute to the current paucity of literature 
regarding the prevention of sarcopenia, while widening 
the evidence base to support existing and future health 
campaigns targeted at sarcopenia.
Contributors DG, GD and SLB-O conceptualised the research question for this 
protocol. All authors edited and revised the research question. DG and SLB-O 
contributed to the development of, and confirmed, the research strategy and 
developed the methodological process. All authors edited, revised and approved the 
methodological process. DG and SLB-O drafted the manuscript. All authors edited 
and contributed to the writing of this paper, read and approved the final version and 
guaranteed the review. 
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Table 2 Criteria for determining evidence level for 
best evidence synthesis: modified from Lievense et al30
Level of evidence
Criteria for inclusion in best 
evidence synthesis
Strong evidence Generally consistent findings in:
 ►Multiple high-quality cohort studies
Moderate evidence Generally consistent findings in:
 ► 1 high-quality cohort study 
and >2 high-quality case-control 
studies
 ► >3 high-quality case–control studies
Limited evidence Generally consistent findings in:
 ► A single cohort study
 ► 1 or 2 case–control studies
 ►Multiple cross-sectional studies
Conflicting evidence Inconsistent findings in <75% of the 
trials
No evidence No studies could be found
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